This ICI-related rapid surge in tumor burden has primarily been reported following PD-1/PD-L1 therapies for lung cancer (Kato et al., 2000; Chubachi et al., 2016; Kurzrock and Kato, 2018; Champiat et al., 2019). Here, PDCD1 is linked to neoplasm.